#Sample Identifier	Patient Identifier	Note	Beta HCG Levels	AFP At Procurement	Date Additional Clinical data added	Date added to cBioPortal	Month added to cBioPortal	Week added to cBioPortal	Detailed Metastatic Site	TNM	Distant Metastasis Pathologic Spread	MYB-NFIB FISH	Run	Site of Recurrence	WHO Grade	MGMT Status	IMPACT pre/post	Matched pre/post (Y/N)	HER2 Amplification Status	HER2 Status	IHC-HER2	HER2 FISH	HER2 Details	Loss of HER2	Stage At Diagnosis	Metastatic Site Other	Time from Dx to IMPACT testing (in months)	Time from obtaining sample to running IMPACT (in months)	PED NCCN Level	PED Driver Mutation	PED Speciment Type	PED Primary Site	PED Stage	PED Disease Category	PED Cancer Type Detailed	Mean Coverage (x)	Neoplasm Histologic Grade	Testes Site of Relapse	Extrathyroidal Extension	Mutation Burden	Specimen Preservation Type	Tumor Side	Phenotype	TTF1 Stain	Tg Stain	CK18 stain	CK7 stain	AE1:AE3 Stain	S-100 stain	34BE12CK STAIN	IHC_CK5/6	P53	CAM 5.2	Neck Dissection type	Mitotic Activity	Necrosis	ENCAPSULATION	CAPSULAR INVASION	Vascular Invasion	Extension	Multicentricity	Positive Finding Lymph Node	Specimen Type	Number Treatment Lines Prior To Receiving Impact Results	Sample pre any Lung Therapy	OncoKB Levels	Driver Mutations	Tumor Sample Histology	Recurrent/metastatic disease	Sort File Number	Clinical Trial Details	Metastases Site First: Lung	Metastases Site First: Liver	Metastases Site First: Ln	Metastases Site First: Pleura	Metastases Site First: Bone	Met IMPACT LUNG	Met IMPACT LIVER	Met IMPACT LN	Met IMPACT BONE	Met IMPACT PLEURA	Met IMPACT ADRENAL	Met Last Follow Up Lung	Met Last Follow Up Liver	Met Last Follow Up Ln	Met Last Follow Up Bone	Met Last Follow Up Pleura	Met Last Follow Up Brain	Met Last Follow Up Adrenal	Met Last Lmd	Met Last Subcutaneous	Met Last Peritoneum	Msk therapeutic clinical trial	Primary Tumor Location	Functional	Sites of metastatic disease	Tumor Differentiation	Mitotic Index	Somatostatin analog therapy	Embolization	Exposure	BIOPSY GLEASON SCORE	CRDB_SURVEY_COMMENTS	Cancer Type	Sample Type	Sample Class	Metastatic Site	Primary Tumor Site	Cancer Type Detailed	Gene Panel	SO comments	Sample coverage	Tumor Purity	Oncotree Code	MSI Comment	MSI Score	MSI Type	Institute Source	Somatic Status	Age at Which Sequencing was Reported (Days)	Archer Panel	Impact TMB Percentile (Across All Tumor Types)	Impact TMB Score	Impact TMB Percentile (Within Tumor Type)	Whole Slide Viewer URL	Stage at first Recurrence	MET Stage	BRAF V600 Level1	BRAF mutation	KIT Level 2A	CKIT Mutation	Sample procurred pre or post immnunotherapy	Other Metastatic Sites Ever per DMT	Mutations	BRCA Germline mutation	MSI MMR	Tumor Disease Anatomic Site	IMPACT Notes	First Site of Metastasis	Resection timing	Histology Secondary	RC Grade	Tissue Sequenced	Bladder MIBC Or Non-MIBC	Bladder Group Grade	Bladder Group Stage	Bladder Group Node Stage	Bladder Group Metastasis Stage	Bladder MIBC No Chemo Progressive	Bladder MIBC Progressivemibc	Bladder MIBC Prior Intravesical Chemotherapy	Bladder MIBC No Chemo Progressiveprior Bcg	Bladder MIBC Specimen Chemotherapy Status	Bladder MIBC Chemo Type	Bladder NMIBC Group	Bladder NMIBC Cis	Bladder NMIBC Tumor Number	Bladder NMIBC Estimated Tumor Size	Bladder NMIBC Adjuvant Mitomycin	Bladder NMIBC Adjuvant Bcg	Bladder NMIBC Recurrence	Bladder NMIBC Time To Recurrence	Bladder NMIBC Ned At 24 Months	Bladder NMIBC High Grade Recurrence	Bladder NMIBC High Grade Recurrence Time	Bladder NMIBC High Grade Ned At 24 Months	Bladder NMIBC Cysto Followup Time	Bladder NMIBC Tcga Smoking Category	Surgery Met	Target Therapy name	Highest actionable level	Type of Surgery	Recurrence to IMPACT (months)	Breast Cancer Receptor Status	ER Status	PR Status	Known Molecular Classifier Primary	Breast Cancer Receptor Status Primary	T Stage	BRCA1 Result	BRCA1 Mutation	BRAC2 Result	BRCA2 Mutation	HPV Status Details	Tumor Size	Nodal Status	IHC For P16	Other Metastasis Sites	Lymph Nodes Metastasis	Level of actionable alterations	Specimen Site	Uterine Weight	If Histology is Sarcoma, specify	Initial Grade	Final Grade	NODES	Lymph nodes aortic examined count	Lymph nodes aortic pos total	Lymph nodes pelvic examined count	Lymph nodes pelvic pos total	Invasion Depth (mm)	Washing	Lymphovascular invasion present	MELF	Extent of Mets	MLH1 Status	MSH2 Status	MSH6 Status	PMS2 Status	Stage at Presentation	Specimen Collection Pre or Post Chemo	PC RPLND Status	S Stage	Primary RPLND	RPLND Path
#A unique sample identifier.	Identifier to uniquely specify a patient.	Note.	Beta HCG Levels	Alpha Fetoprotein At Procurement	Date Additional Clinical data added	Date added to cBioPortal	Month added to cBioPortal	Week added to cBioPortal	Detailed Metastatic Site	TNM.	Distant metastasis pathologic spread.	MYB-NFIB FISH.	Run-IMPACT	Site of Recurrence	WHO Grade	MGMT Status	IMPACT pre/post	Matched pre/post (Y/N)	HER2 Amplification Status	HER2 Status	IHC-HER2	HER2 FISH	HER2 Details	Loss of HER2	Stage At Diagnosis	Metastatic Site Other	Time from Dx to IMPACT testing (in months)	Time from obtaining sample to running IMPACT (in months)	PED NCCN Level	PED Driver Mutation	PED Speciment Type	PED Primary Site	PED Stage	PED Disease Category	PED Cancer Type Detailed	Mean Coverage (x)	Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness.	Testes Site of Relapse	Extrathyroidal Extension	Mutation Burden	The method used for preparing the tissue for examination and study.	Tumor side.	Phenotype	TTF1 Stain	Tg Stain	CK18 stain	CK7 stain	AE1:AE3 Stain	S-100 Stain	34BE12CK STAIN	IHC_CK5/6	P53.	CAM 5.2	Neck Dissection type	Mitotic Activity	Necrosis	ENCAPSULATION	CAPSULAR INVASION	Vascular invasion.	Extension	Multicentricity	Positive Finding Lymph Node	The broad cancer phenotype and site information values for a sample to be processed.	Number Treatment Lines Prior To Receiving Impact Results	Sample pre any Lung Therapy	OncoKB Levels	Driver Mutations	Tumor Sample Histology	Recurrent/metastatic disease	Sort File Number	Clinical Trial Details	Metastases Site First: Lung	Metastases Site First: Liver	Metastases Site First: Ln	Metastases Site First: Pleura	Metastases Site First: Bone	Met IMPACT LUNG	Met IMPACT LIVER	Met IMPACT LN	Met IMPACT BONE	Met IMPACT PLEURA	Met IMPACT ADRENAL	Met Last Follow Up Lung	Met Last Follow Up Liver	Met Last Follow Up Ln	Met Last Follow Up Bone	Met Last Follow Up Pleura	Met Last Follow Up Brain	Met Last Follow Up Adrenal	Met Last Lmd	Met Last Subcutaneous	Met Last Peritoneum	Msk therapeutic clinical trial	Primary Tumor Location	Functional	Sites of metastatic disease	Tumor Differentiation	Mitotic Index	Somatostatin analog therapy	Embolization	Exposure	BIOPSY GLEASON SCORE	The survey comments at enrollment for 12-245.	Cancer Type	The type of sample (i.e., normal, primary, met, recurrence).	The sample classification (i.e., tumor, cellline, xenograph).	The anatomic location to which the cancer has spread.	Text term to describe the organ sub-division in an individual with cancer.	Cancer Type Detailed	Gene panel.	Sign-out comments	Sample coverage	Tumor Purity	Oncotree Code	MSI Comment	MSI Score	MSI Type	Institute Source	Somatic Status	Age (in days) at which sequencing was reported	Archer Panel	Percentile for the TMB within the MSK-IMAPCT cohort	Calculated TMB score	Percentile for the TMB within the Tumor type cohort (at least 10 cases are needed in that tumor type to have a result for this)	URL to Computational Pathology-Whole Slide Viewer	Stage at first Recurrence	MET Stage	BRAF V600 Level1	BRAF mutation	KIT Level 2A	CKIT mutation.	Sample procurred pre or post immnunotherapy	Other Metastatic Sites Ever per DMT	Mutations	BRCA Germline mutation	MSI MMR	Text term that describes the anatomic site of the tumor or disease.	IMPACT Notes	First Site of Metastasis	Resection timing	Histology Secondary	RC Grade	Tissue Sequnced	Bladder MIBC Or Non-MIBC	Bladder Group Grade	Bladder Group Stage	Bladder Group Node Stage	Bladder Group Metastasis Stage	Bladder MIBC No Chemo Progressive	Bladder MIBC Progressivemibc	Bladder MIBC Prior Intravesical Chemotherapy	Bladder MIBC No Chemo Progressiveprior Bcg	Bladder MIBC Specimen Chemotherapy Status	Bladder MIBC Chemo Type	Bladder NMIBC Group	Bladder NMIBC Cis	Bladder NMIBC Tumor Number	Bladder NMIBC Estimated Tumor Size	Bladder NMIBC Adjuvant Mitomycin	Bladder NMIBC Adjuvant Bcg	Bladder NMIBC Recurrence	Bladder NMIBC Time To Recurrence	Bladder NMIBC Ned At 24 Months	Bladder NMIBC High Grade Recurrence	Bladder NMIBC High Grade Recurrence Time	Bladder NMIBC High Grade Ned At 24 Months	Bladder NMIBC Cysto Followup Time	Bladder NMIBC Tcga Smoking Category	Surgery Met	Target Therapy name	Highest actionable level	Type of Surgery.	Recurrence to IMPACT (months)	Breast Cancer Receptor Status	ER Status	PR Status	Known Molecular Classifier Primary	Breast Cancer Receptor Status Primary	T Stage	BRCA1 Result	BRCA1 Mutation is present	BRAC2 Result	BRCA2 Mutation is present	HPV Status Details	Tumor size.	Nodal Status	IHC For P16	Other Metastasis Sites Description	Lymph nodes metastasis.	Level of actionable alterations	Specimen Site	Uterine Weight	If Histology defined is Sarcoma, please specify what type of Sarcoma	Initial Grade	Final Grade	NODES	Lymph nodes aortic examined count	Lymph nodes aortic pos total	Lymph nodes pelvic examined count	Lymph nodes pelvic pos total	Invasion depth (mm).	Washing	Lymphovascular invasion present	MELF	Extent of Mets	MLH1 Status	MSH2 Status	MSH6 Status	PMS2 Status	Stage at Presentation	Specimen Collection Pre or Post Chemo	PC RPLND Status	S indicates the serum (blood) levels of tumor markers that are made by some testicular cancers	Primary RPLND	RPLND Path
#STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	NUMBER	STRING	STRING	STRING	NUMBER	STRING	NUMBER	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	NUMBER	NUMBER	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING
#0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SAMPLE_ID	PATIENT_ID	NOTE	BETA_HCG_LEVELS	AFP_AT_PROCUREMENT	DATE_ADDITIONAL_CLINICAL_DATA_ADDED	DATE_ADDED	MONTH_ADDED	WEEK_ADDED	DETAILED_METASTATIC_SITE	TNM	DISTANT_METASTASIS_PATHOLOGIC_SPREAD	MYB_NFIB_FISH	RUN	SITE_OF_RECURRENCE	WHO_GRADE	MGMT_STATUS	IMPACT_PRE_POST	MATCHED_PRE_POST	HER2_AMPLIFICATION_STATUS	HER2_STATUS	IHC_HER2	HER2_FISH	HER2_DETAILS	LOSS_OF_HER2	STAGE_AT_DIAGNOSIS	METASTATIC_SITE_OTHER	TIME_FROM_DX_TO_IMPACT_TESTING_MONTHS	TIME_FROM_OBTAINING_SAMPLE_TO_RUNNING_IMPACT_MONTHS	PED_NCCN_LEVEL	PED_DRIVER_MUTATION	PED_SPECIMEN_TYPE	PED_PRIMARY_SITE	PED_STAGE	PED_DISEASE_CATEGORY	PEDS_CANCER_TYPE_DETAILED	MEAN_COVERAGE	GRADE	TESTES_SITE_OF_RELAPSE	EXTRATHYROIDAL_EXTENSION	MUTATION_BURDEN	SPECIMEN_PRESERVATION_TYPE	TUMOR_SIDE	PHENOTYPE	TTF1_STAIN	TG_STAIN	CK18_STAIN	CK7_STAIN	AE1_AE3_STAIN	S_100_STAIN	STAIN_34BE12CK	IHC_CK5_6	P53	CAM_5_2	NECK_DISSECTION_TYPE	MITOTIC_ACTIVITY	NECROSIS	ENCAPSULATION	CAPSULAR_INVASION	VASCULAR_INVASION	EXTENSION	MULTICENTRICITY	NUMBER_OF_LYMPHNODES_POSITIVE	SPECIMEN_TYPE	LINES_OF_TX_PRIOR_IMPACT	SAMPLE_PRE_LUNG_THERAPY	ONCOKB_LEVELS	DRIVER_MUTATIONS	TUMOR_SAMPLE_HISTOLOGY	RECURRENT_METASTATIC_DISEASE	SORT_FILE_NUMBER	CLINICAL_TRIAL_DETAILS	METASTASES_SITE_FIRST_LUNG	METASTASES_SITE_FIRST_LIVER	METASTASES_SITE_FIRST_LN	METASTASES_SITE_FIRST_PLEURA	METASTASES_SITE_FIRST_BONE	MET_IMPACT_LUNG	MET_IMPACT_LIVER	MET_IMPACT_LN	MET_IMPACT_BONE	MET_IMPACT_PLEURA	MET_IMPACT_ADRENAL	MET_LAST_FUP_LUNG	MET_LAST_FUP_LIVER	MET_LAST_FUP_LN	MET_LAST_FUP_BONE	MET_LAST_FUP_PLEURA	MET_LAST_FUP_BRAIN	MET_LAST_FUP_ADRENAL	MET_LAST_LMD	MET_LAST_SUBCUTANEOUS	MET_LAST_PERITONEUM	MSK_THERAPEUTIC_CLINICAL_TRIAL	PRIMARY_TUMOR_LOCATION	FUNCTIONAL	SITES_OF_METASTATIC_DISEASE	TUMOR_DIFFERENTIATION	MITOTIC_INDEX	SOMATOSTATIN_ANALOG_THERAPY	EMBOLIZATION	EXPOSURE	BIOPSY_GLEASON_SCORE	CRDB_SURVEY_COMMENTS	CANCER_TYPE	SAMPLE_TYPE	SAMPLE_CLASS	METASTATIC_SITE	PRIMARY_SITE	CANCER_TYPE_DETAILED	GENE_PANEL	SO_COMMENTS	SAMPLE_COVERAGE	TUMOR_PURITY	ONCOTREE_CODE	MSI_COMMENT	MSI_SCORE	MSI_TYPE	INSTITUTE	SOMATIC_STATUS	AGE_AT_SEQ_REPORT	ARCHER	CVR_TMB_COHORT_PERCENTILE	CVR_TMB_SCORE	CVR_TMB_TT_COHORT_PERCENTILE	COMP_PATH_WSV_URL	STAGE_AT_FIRST_RECURRENCE	METASTATIC_STAGE	BRAF_V600_LEVEL1	BRAF_MUTATION	KIT_LEVEL_2A	CKIT_MUTATION	SAMPLE_PRE_POST_IMMUNE	MET_SITE_OTHER_DMT	MUTATIONS	BRCA_GERMLINE_MUTATIONS	MSI_MMR	TUMOR_TISSUE_SITE	IMPACT_NOTES	FIRST_SITE_OF_METS	RESECTION_TIMING	SECONDARY_HISTOLOGY	RC_GRADE	TISSUE_SEQUENCED	BLADDER_MIBC_OR_NON_MIBC	BLADDER_GROUP_GRADE	BLADDER_GROUP_STAGE	BLADDER_GROUP_NODE_STAGE	BLADDER_GROUP_METASTASIS_STAGE	BLADDER_MIBC_NO_CHEMO_PROGRESSIVE	BLADDER_MIBC_PROGRESSIVE	BLADDER_MIBC_PRIOR_INTRAVESICAL_CHEMOTHERAPY	BLADDER_MIBC_NO_CHEMO_PROGRESSIVEPRIOR_BCG	BLADDER_MIBC_SPECIMEN_CHEMOTHERAPY_STATUS	BLADDER_MIBC_CHEMO_TYPE	BLADDER_NMIBC_GROUP	BLADDER_NMIBC_CIS	BLADDER_NMIBC_TUMOR_NUMBER	BLADDER_NMIBC_ESTIMATED_TUMOR_SIZE	BLADDER_NMIBC_ADJUVANT_MITOMYCIN	BLADDER_NMIBC_ADJUVANT_BCG	BLADDER_NMIBC_RECURRENCE	BLADDER_NMIBC_TIME_TO_RECURRENCE	BLADDER_NMIBC_NED_AT_24_MONTHS	BLADDER_NMIBC_HIGH_GRADE_RECURRENCE	BLADDER_NMIBC_HIGH_GRADE_RECURR_TIME	BLADDER_NMIBC_HIGH_GRADE_NED_AT_24_MONTHS	BLADDER_NMIBC_CYSTO_FUPTIME	BLADDER_NMIBC_TCGA_SMOKING_CATEGORY	SURGERY_MET	TARGET_THERAPY_NAME	HIGHEST_ACTIONABLE_LEVEL	TYPE_OF_SURGERY	RECUR_TO_IMPACT_EXTENT_MONTHS	BREAST_CANCER_RECEPTOR_STATUS	ER_STATUS	PR_STATUS	KNOWN_MOLECULAR_CLASSIFIER_PRIMARY	BREAST_CANCER_RECEPTOR_STATUS_PRIMARY	T_STAGE	BRCA1_RESULT	BRCA1_MUTATION	BRCA2_RESULT	BRCA2_MUTATION	HPV_DETAILS	TUMOR_SIZE	NODAL_STATUS	IHC_P16	OTHER_SITES_OF_METS	LYMPH_NODE_METASTASIS	ACTIONABLE_ALT_LEVEL	SPECIMEN_SITE	UTERINE_WEIGHT	IF_SARCOMA_SPECIFY	INITIAL_GRADE	FINAL_GRADE	NODES	LYMPH_NODES_AORTIC_EXAMINED_COUNT	LYMPH_NODES_AORTIC_POS_TOTAL	LYMPH_NODES_PELVIC_EXAMINED_COUNT	LYMPH_NODES_PELVIC_POS_TOTAL	INVASION_DEPTH	WASHING	LYMPHOVASCULAR_INVASION_PRESENT	MELF	EXTENT_OF_METS	MLH1_STATUS	MSH2_STATUS	MSH6_STATUS	PMS2_STATUS	STAGE_AT_PRESENTATION	SPECIMEN_COLLECTION_PRE_OR_POST_CHEMO	PC_RPLND_STATUS	S_STAGE	PRIMARY_RPLND	RPLND_PATH
P-0003533-T01-IM5	P-0003533					2018/11/02	2018/11	2018, Wk. 44																																																																																																Mixed Germ Cell Tumor	Primary	Tumor	Not Applicable	Mediastinum	Mixed Germ Cell Tumor	IMPACT410		541	10	MGCT				MSKCC	Matched	21	NO	25.2	2.0	62.6																																																																																							post				
#Sample Identifier	Patient Identifier	Note	Beta HCG Levels	AFP At Procurement	Date Additional Clinical data added	Date added to cBioPortal	Month added to cBioPortal	Week added to cBioPortal	Detailed Metastatic Site	TNM	Distant Metastasis Pathologic Spread	MYB-NFIB FISH	Run	Site of Recurrence	WHO Grade	MGMT Status	IMPACT pre/post	Matched pre/post (Y/N)	HER2 Amplification Status	HER2 Status	IHC-HER2	HER2 FISH	HER2 Details	Loss of HER2	Stage At Diagnosis	Metastatic Site Other	Time from Dx to IMPACT testing (in months)	Time from obtaining sample to running IMPACT (in months)	PED NCCN Level	PED Driver Mutation	PED Speciment Type	PED Primary Site	PED Stage	PED Disease Category	PED Cancer Type Detailed	Mean Coverage (x)	Neoplasm Histologic Grade	Testes Site of Relapse	Extrathyroidal Extension	Mutation Burden	Specimen Preservation Type	Tumor Side	Phenotype	TTF1 Stain	Tg Stain	CK18 stain	CK7 stain	AE1:AE3 Stain	S-100 stain	34BE12CK STAIN	IHC_CK5/6	P53	CAM 5.2	Neck Dissection type	Mitotic Activity	Necrosis	ENCAPSULATION	CAPSULAR INVASION	Vascular Invasion	Extension	Multicentricity	Positive Finding Lymph Node	Specimen Type	Number Treatment Lines Prior To Receiving Impact Results	Sample pre any Lung Therapy	OncoKB Levels	Driver Mutations	Tumor Sample Histology	Recurrent/metastatic disease	Sort File Number	Clinical Trial Details	Metastases Site First: Lung	Metastases Site First: Liver	Metastases Site First: Ln	Metastases Site First: Pleura	Metastases Site First: Bone	Met IMPACT LUNG	Met IMPACT LIVER	Met IMPACT LN	Met IMPACT BONE	Met IMPACT PLEURA	Met IMPACT ADRENAL	Met Last Follow Up Lung	Met Last Follow Up Liver	Met Last Follow Up Ln	Met Last Follow Up Bone	Met Last Follow Up Pleura	Met Last Follow Up Brain	Met Last Follow Up Adrenal	Met Last Lmd	Met Last Subcutaneous	Met Last Peritoneum	Msk therapeutic clinical trial	Primary Tumor Location	Functional	Sites of metastatic disease	Tumor Differentiation	Mitotic Index	Somatostatin analog therapy	Embolization	Exposure	BIOPSY GLEASON SCORE	CRDB_SURVEY_COMMENTS	Cancer Type	Sample Type	Sample Class	Metastatic Site	Primary Tumor Site	Cancer Type Detailed	Gene Panel	SO comments	Sample coverage	Tumor Purity	Oncotree Code	MSI Comment	MSI Score	MSI Type	Institute Source	Somatic Status	Age at Which Sequencing was Reported (Days)	Archer Panel	Impact TMB Percentile (Across All Tumor Types)	Impact TMB Score	Impact TMB Percentile (Within Tumor Type)	Whole Slide Viewer URL	Stage at first Recurrence	MET Stage	BRAF V600 Level1	BRAF mutation	KIT Level 2A	CKIT Mutation	Sample procurred pre or post immnunotherapy	Other Metastatic Sites Ever per DMT	Mutations	BRCA Germline mutation	MSI MMR	Tumor Disease Anatomic Site	IMPACT Notes	First Site of Metastasis	Resection timing	Histology Secondary	RC Grade	Tissue Sequenced	Bladder MIBC Or Non-MIBC	Bladder Group Grade	Bladder Group Stage	Bladder Group Node Stage	Bladder Group Metastasis Stage	Bladder MIBC No Chemo Progressive	Bladder MIBC Progressivemibc	Bladder MIBC Prior Intravesical Chemotherapy	Bladder MIBC No Chemo Progressiveprior Bcg	Bladder MIBC Specimen Chemotherapy Status	Bladder MIBC Chemo Type	Bladder NMIBC Group	Bladder NMIBC Cis	Bladder NMIBC Tumor Number	Bladder NMIBC Estimated Tumor Size	Bladder NMIBC Adjuvant Mitomycin	Bladder NMIBC Adjuvant Bcg	Bladder NMIBC Recurrence	Bladder NMIBC Time To Recurrence	Bladder NMIBC Ned At 24 Months	Bladder NMIBC High Grade Recurrence	Bladder NMIBC High Grade Recurrence Time	Bladder NMIBC High Grade Ned At 24 Months	Bladder NMIBC Cysto Followup Time	Bladder NMIBC Tcga Smoking Category	Surgery Met	Target Therapy name	Highest actionable level	Type of Surgery	Recurrence to IMPACT (months)	Breast Cancer Receptor Status	ER Status	PR Status	Known Molecular Classifier Primary	Breast Cancer Receptor Status Primary	T Stage	BRCA1 Result	BRCA1 Mutation	BRAC2 Result	BRCA2 Mutation	HPV Status Details	Tumor Size	Nodal Status	IHC For P16	Other Metastasis Sites	Lymph Nodes Metastasis	Level of actionable alterations	Specimen Site	Uterine Weight	If Histology is Sarcoma, specify	Initial Grade	Final Grade	NODES	Lymph nodes aortic examined count	Lymph nodes aortic pos total	Lymph nodes pelvic examined count	Lymph nodes pelvic pos total	Invasion Depth (mm)	Washing	Lymphovascular invasion present	MELF	Extent of Mets	MLH1 Status	MSH2 Status	MSH6 Status	PMS2 Status	Stage at Presentation	Specimen Collection Pre or Post Chemo	PC RPLND Status	S Stage	Primary RPLND	RPLND Path
#A unique sample identifier.	Identifier to uniquely specify a patient.	Note.	Beta HCG Levels	Alpha Fetoprotein At Procurement	Date Additional Clinical data added	Date added to cBioPortal	Month added to cBioPortal	Week added to cBioPortal	Detailed Metastatic Site	TNM.	Distant metastasis pathologic spread.	MYB-NFIB FISH.	Run-IMPACT	Site of Recurrence	WHO Grade	MGMT Status	IMPACT pre/post	Matched pre/post (Y/N)	HER2 Amplification Status	HER2 Status	IHC-HER2	HER2 FISH	HER2 Details	Loss of HER2	Stage At Diagnosis	Metastatic Site Other	Time from Dx to IMPACT testing (in months)	Time from obtaining sample to running IMPACT (in months)	PED NCCN Level	PED Driver Mutation	PED Speciment Type	PED Primary Site	PED Stage	PED Disease Category	PED Cancer Type Detailed	Mean Coverage (x)	Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness.	Testes Site of Relapse	Extrathyroidal Extension	Mutation Burden	The method used for preparing the tissue for examination and study.	Tumor side.	Phenotype	TTF1 Stain	Tg Stain	CK18 stain	CK7 stain	AE1:AE3 Stain	S-100 Stain	34BE12CK STAIN	IHC_CK5/6	P53.	CAM 5.2	Neck Dissection type	Mitotic Activity	Necrosis	ENCAPSULATION	CAPSULAR INVASION	Vascular invasion.	Extension	Multicentricity	Positive Finding Lymph Node	The broad cancer phenotype and site information values for a sample to be processed.	Number Treatment Lines Prior To Receiving Impact Results	Sample pre any Lung Therapy	OncoKB Levels	Driver Mutations	Tumor Sample Histology	Recurrent/metastatic disease	Sort File Number	Clinical Trial Details	Metastases Site First: Lung	Metastases Site First: Liver	Metastases Site First: Ln	Metastases Site First: Pleura	Metastases Site First: Bone	Met IMPACT LUNG	Met IMPACT LIVER	Met IMPACT LN	Met IMPACT BONE	Met IMPACT PLEURA	Met IMPACT ADRENAL	Met Last Follow Up Lung	Met Last Follow Up Liver	Met Last Follow Up Ln	Met Last Follow Up Bone	Met Last Follow Up Pleura	Met Last Follow Up Brain	Met Last Follow Up Adrenal	Met Last Lmd	Met Last Subcutaneous	Met Last Peritoneum	Msk therapeutic clinical trial	Primary Tumor Location	Functional	Sites of metastatic disease	Tumor Differentiation	Mitotic Index	Somatostatin analog therapy	Embolization	Exposure	BIOPSY GLEASON SCORE	The survey comments at enrollment for 12-245.	Cancer Type	The type of sample (i.e., normal, primary, met, recurrence).	The sample classification (i.e., tumor, cellline, xenograph).	The anatomic location to which the cancer has spread.	Text term to describe the organ sub-division in an individual with cancer.	Cancer Type Detailed	Gene panel.	Sign-out comments	Sample coverage	Tumor Purity	Oncotree Code	MSI Comment	MSI Score	MSI Type	Institute Source	Somatic Status	Age (in days) at which sequencing was reported	Archer Panel	Percentile for the TMB within the MSK-IMAPCT cohort	Calculated TMB score	Percentile for the TMB within the Tumor type cohort (at least 10 cases are needed in that tumor type to have a result for this)	URL to Computational Pathology-Whole Slide Viewer	Stage at first Recurrence	MET Stage	BRAF V600 Level1	BRAF mutation	KIT Level 2A	CKIT mutation.	Sample procurred pre or post immnunotherapy	Other Metastatic Sites Ever per DMT	Mutations	BRCA Germline mutation	MSI MMR	Text term that describes the anatomic site of the tumor or disease.	IMPACT Notes	First Site of Metastasis	Resection timing	Histology Secondary	RC Grade	Tissue Sequnced	Bladder MIBC Or Non-MIBC	Bladder Group Grade	Bladder Group Stage	Bladder Group Node Stage	Bladder Group Metastasis Stage	Bladder MIBC No Chemo Progressive	Bladder MIBC Progressivemibc	Bladder MIBC Prior Intravesical Chemotherapy	Bladder MIBC No Chemo Progressiveprior Bcg	Bladder MIBC Specimen Chemotherapy Status	Bladder MIBC Chemo Type	Bladder NMIBC Group	Bladder NMIBC Cis	Bladder NMIBC Tumor Number	Bladder NMIBC Estimated Tumor Size	Bladder NMIBC Adjuvant Mitomycin	Bladder NMIBC Adjuvant Bcg	Bladder NMIBC Recurrence	Bladder NMIBC Time To Recurrence	Bladder NMIBC Ned At 24 Months	Bladder NMIBC High Grade Recurrence	Bladder NMIBC High Grade Recurrence Time	Bladder NMIBC High Grade Ned At 24 Months	Bladder NMIBC Cysto Followup Time	Bladder NMIBC Tcga Smoking Category	Surgery Met	Target Therapy name	Highest actionable level	Type of Surgery.	Recurrence to IMPACT (months)	Breast Cancer Receptor Status	ER Status	PR Status	Known Molecular Classifier Primary	Breast Cancer Receptor Status Primary	T Stage	BRCA1 Result	BRCA1 Mutation is present	BRAC2 Result	BRCA2 Mutation is present	HPV Status Details	Tumor size.	Nodal Status	IHC For P16	Other Metastasis Sites Description	Lymph nodes metastasis.	Level of actionable alterations	Specimen Site	Uterine Weight	If Histology defined is Sarcoma, please specify what type of Sarcoma	Initial Grade	Final Grade	NODES	Lymph nodes aortic examined count	Lymph nodes aortic pos total	Lymph nodes pelvic examined count	Lymph nodes pelvic pos total	Invasion depth (mm).	Washing	Lymphovascular invasion present	MELF	Extent of Mets	MLH1 Status	MSH2 Status	MSH6 Status	PMS2 Status	Stage at Presentation	Specimen Collection Pre or Post Chemo	PC RPLND Status	S indicates the serum (blood) levels of tumor markers that are made by some testicular cancers	Primary RPLND	RPLND Path
#STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	NUMBER	STRING	STRING	STRING	NUMBER	STRING	NUMBER	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	NUMBER	NUMBER	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING
#0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SAMPLE_ID	PATIENT_ID	NOTE	BETA_HCG_LEVELS	AFP_AT_PROCUREMENT	DATE_ADDITIONAL_CLINICAL_DATA_ADDED	DATE_ADDED	MONTH_ADDED	WEEK_ADDED	DETAILED_METASTATIC_SITE	TNM	DISTANT_METASTASIS_PATHOLOGIC_SPREAD	MYB_NFIB_FISH	RUN	SITE_OF_RECURRENCE	WHO_GRADE	MGMT_STATUS	IMPACT_PRE_POST	MATCHED_PRE_POST	HER2_AMPLIFICATION_STATUS	HER2_STATUS	IHC_HER2	HER2_FISH	HER2_DETAILS	LOSS_OF_HER2	STAGE_AT_DIAGNOSIS	METASTATIC_SITE_OTHER	TIME_FROM_DX_TO_IMPACT_TESTING_MONTHS	TIME_FROM_OBTAINING_SAMPLE_TO_RUNNING_IMPACT_MONTHS	PED_NCCN_LEVEL	PED_DRIVER_MUTATION	PED_SPECIMEN_TYPE	PED_PRIMARY_SITE	PED_STAGE	PED_DISEASE_CATEGORY	PEDS_CANCER_TYPE_DETAILED	MEAN_COVERAGE	GRADE	TESTES_SITE_OF_RELAPSE	EXTRATHYROIDAL_EXTENSION	MUTATION_BURDEN	SPECIMEN_PRESERVATION_TYPE	TUMOR_SIDE	PHENOTYPE	TTF1_STAIN	TG_STAIN	CK18_STAIN	CK7_STAIN	AE1_AE3_STAIN	S_100_STAIN	STAIN_34BE12CK	IHC_CK5_6	P53	CAM_5_2	NECK_DISSECTION_TYPE	MITOTIC_ACTIVITY	NECROSIS	ENCAPSULATION	CAPSULAR_INVASION	VASCULAR_INVASION	EXTENSION	MULTICENTRICITY	NUMBER_OF_LYMPHNODES_POSITIVE	SPECIMEN_TYPE	LINES_OF_TX_PRIOR_IMPACT	SAMPLE_PRE_LUNG_THERAPY	ONCOKB_LEVELS	DRIVER_MUTATIONS	TUMOR_SAMPLE_HISTOLOGY	RECURRENT_METASTATIC_DISEASE	SORT_FILE_NUMBER	CLINICAL_TRIAL_DETAILS	METASTASES_SITE_FIRST_LUNG	METASTASES_SITE_FIRST_LIVER	METASTASES_SITE_FIRST_LN	METASTASES_SITE_FIRST_PLEURA	METASTASES_SITE_FIRST_BONE	MET_IMPACT_LUNG	MET_IMPACT_LIVER	MET_IMPACT_LN	MET_IMPACT_BONE	MET_IMPACT_PLEURA	MET_IMPACT_ADRENAL	MET_LAST_FUP_LUNG	MET_LAST_FUP_LIVER	MET_LAST_FUP_LN	MET_LAST_FUP_BONE	MET_LAST_FUP_PLEURA	MET_LAST_FUP_BRAIN	MET_LAST_FUP_ADRENAL	MET_LAST_LMD	MET_LAST_SUBCUTANEOUS	MET_LAST_PERITONEUM	MSK_THERAPEUTIC_CLINICAL_TRIAL	PRIMARY_TUMOR_LOCATION	FUNCTIONAL	SITES_OF_METASTATIC_DISEASE	TUMOR_DIFFERENTIATION	MITOTIC_INDEX	SOMATOSTATIN_ANALOG_THERAPY	EMBOLIZATION	EXPOSURE	BIOPSY_GLEASON_SCORE	CRDB_SURVEY_COMMENTS	CANCER_TYPE	SAMPLE_TYPE	SAMPLE_CLASS	METASTATIC_SITE	PRIMARY_SITE	CANCER_TYPE_DETAILED	GENE_PANEL	SO_COMMENTS	SAMPLE_COVERAGE	TUMOR_PURITY	ONCOTREE_CODE	MSI_COMMENT	MSI_SCORE	MSI_TYPE	INSTITUTE	SOMATIC_STATUS	AGE_AT_SEQ_REPORT	ARCHER	CVR_TMB_COHORT_PERCENTILE	CVR_TMB_SCORE	CVR_TMB_TT_COHORT_PERCENTILE	COMP_PATH_WSV_URL	STAGE_AT_FIRST_RECURRENCE	METASTATIC_STAGE	BRAF_V600_LEVEL1	BRAF_MUTATION	KIT_LEVEL_2A	CKIT_MUTATION	SAMPLE_PRE_POST_IMMUNE	MET_SITE_OTHER_DMT	MUTATIONS	BRCA_GERMLINE_MUTATIONS	MSI_MMR	TUMOR_TISSUE_SITE	IMPACT_NOTES	FIRST_SITE_OF_METS	RESECTION_TIMING	SECONDARY_HISTOLOGY	RC_GRADE	TISSUE_SEQUENCED	BLADDER_MIBC_OR_NON_MIBC	BLADDER_GROUP_GRADE	BLADDER_GROUP_STAGE	BLADDER_GROUP_NODE_STAGE	BLADDER_GROUP_METASTASIS_STAGE	BLADDER_MIBC_NO_CHEMO_PROGRESSIVE	BLADDER_MIBC_PROGRESSIVE	BLADDER_MIBC_PRIOR_INTRAVESICAL_CHEMOTHERAPY	BLADDER_MIBC_NO_CHEMO_PROGRESSIVEPRIOR_BCG	BLADDER_MIBC_SPECIMEN_CHEMOTHERAPY_STATUS	BLADDER_MIBC_CHEMO_TYPE	BLADDER_NMIBC_GROUP	BLADDER_NMIBC_CIS	BLADDER_NMIBC_TUMOR_NUMBER	BLADDER_NMIBC_ESTIMATED_TUMOR_SIZE	BLADDER_NMIBC_ADJUVANT_MITOMYCIN	BLADDER_NMIBC_ADJUVANT_BCG	BLADDER_NMIBC_RECURRENCE	BLADDER_NMIBC_TIME_TO_RECURRENCE	BLADDER_NMIBC_NED_AT_24_MONTHS	BLADDER_NMIBC_HIGH_GRADE_RECURRENCE	BLADDER_NMIBC_HIGH_GRADE_RECURR_TIME	BLADDER_NMIBC_HIGH_GRADE_NED_AT_24_MONTHS	BLADDER_NMIBC_CYSTO_FUPTIME	BLADDER_NMIBC_TCGA_SMOKING_CATEGORY	SURGERY_MET	TARGET_THERAPY_NAME	HIGHEST_ACTIONABLE_LEVEL	TYPE_OF_SURGERY	RECUR_TO_IMPACT_EXTENT_MONTHS	BREAST_CANCER_RECEPTOR_STATUS	ER_STATUS	PR_STATUS	KNOWN_MOLECULAR_CLASSIFIER_PRIMARY	BREAST_CANCER_RECEPTOR_STATUS_PRIMARY	T_STAGE	BRCA1_RESULT	BRCA1_MUTATION	BRCA2_RESULT	BRCA2_MUTATION	HPV_DETAILS	TUMOR_SIZE	NODAL_STATUS	IHC_P16	OTHER_SITES_OF_METS	LYMPH_NODE_METASTASIS	ACTIONABLE_ALT_LEVEL	SPECIMEN_SITE	UTERINE_WEIGHT	IF_SARCOMA_SPECIFY	INITIAL_GRADE	FINAL_GRADE	NODES	LYMPH_NODES_AORTIC_EXAMINED_COUNT	LYMPH_NODES_AORTIC_POS_TOTAL	LYMPH_NODES_PELVIC_EXAMINED_COUNT	LYMPH_NODES_PELVIC_POS_TOTAL	INVASION_DEPTH	WASHING	LYMPHOVASCULAR_INVASION_PRESENT	MELF	EXTENT_OF_METS	MLH1_STATUS	MSH2_STATUS	MSH6_STATUS	PMS2_STATUS	STAGE_AT_PRESENTATION	SPECIMEN_COLLECTION_PRE_OR_POST_CHEMO	PC_RPLND_STATUS	S_STAGE	PRIMARY_RPLND	RPLND_PATH
P-0003533-T03-IM5	P-0003533					2018/11/02	2018/11	2018, Wk. 44																																																																																																Teratoma with Malignant Transformation	Metastasis	Tumor	Spleen	Mediastinum	Teratoma with Malignant Transformation	IMPACT410		798	20	TMT				MSKCC	Matched	21	NO	37.9	3.0	78.8																																																																																											
